Format

Send to

Choose Destination
Recenti Prog Med. 2016 Apr;107(4):193-8. doi: 10.1701/2218.23932.

[Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer: Poliambulanza experience].

[Article in Italian]

Author information

1
UO di Oncologia, Fondazione Poliambulanza, Brescia, Italia.

Abstract

We reported the cases of two patients affected by metastatic gastric cancer exposed to second line therapy with ramucirumab plus paclitaxel after progression. Both obtained a fast marker reduction with a very favourable toxicity profile. In the first case, a woman affected by peritoneal carcinomatosis, the disease had been stable for 8 months despite of the chemotherapy suspension after 3 cycles; whereas in the second case, a highly symptomatic man with a heavy tumor load (gastric tumor and multiple bone, node and peritoneal metastases) obtained an immediate clinical benefit even if of relatively short duration with a good tolerability.

PMID:
27093329
DOI:
10.1701/2218.23932
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Il Pensiero Scientifico Editore
Loading ...
Support Center